Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)
Status:
Unknown status
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
To evaluate efficacy and safety of S-1 Oxaliplatin (SOX) regimen to patients with
unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma.